Featured Research

from universities, journals, and other organizations

Gefitinib may have chemopreventive benefits in pancreatic cancer

Date:
November 8, 2010
Source:
American Association for Cancer Research
Summary:
Gefitinib may be a promising chemoprevention agent for pancreatic cancer, according to new study.

Gefitinib may be a promising chemoprevention agent for pancreatic cancer, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

The study is published in the November issue, and was discussed during a press conference at the Ninth Annual Frontiers in Cancer Prevention Research Conference, held here Nov. 7-10, 2010.

Pancreatic cancer has a dismal prognosis because it is often asymptomatic and not detected until it is in late stages. Strategies to combat pancreatic cancer have focused on earlier and earlier treatments, and this is the first time that a chemoprevention strategy has been tried.

Chinthalapally V. Rao, Ph.D., director of the Center for Chemoprevention and Cancer Drug Development at the University of Oklahoma Cancer Institute, tested the strategy in mice.

The mice were bred to be at high risk for pancreatic cancer and then fed gefitinib in escalating doses of 0, 100 and 200 ppm for a period of 35 weeks, at which time the tumor incidence was analyzed.

Compared to the group that received no gefitinib, the mid-dose group experienced 77 percent fewer pancreatic tumors and the high-dose group had 100 percent fewer tumors.

In the 100 ppm group, 67.6 percent of the mice were free of pancreatic intraepithelial neoplasms, a known pre-cursor to pancreatic cancer, compared with 77.3 percent in the 200 ppm group.

"These findings are dramatic enough that human trials should begin soon," said Rao. "The clear message is that the earlier we start, the better the outcome is, and we can already measure neoplasm levels in humans so there is a potential here for clinical benefit."


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. A. Mohammed, N. B. Janakiram, Q. Li, V. Madka, M. Ely, S. Lightfoot, H. Crawford, V. E. Steele, C. V. Rao. The Epidermal Growth Factor Receptor Inhibitor Gefitinib Prevents the Progression of Pancreatic Lesions to Carcinoma in a Conditional LSL-KrasG12D/+ Transgenic Mouse Model. Cancer Prevention Research, 2010; 3 (11): 1417 DOI: 10.1158/1940-6207.CAPR-10-0038

Cite This Page:

American Association for Cancer Research. "Gefitinib may have chemopreventive benefits in pancreatic cancer." ScienceDaily. ScienceDaily, 8 November 2010. <www.sciencedaily.com/releases/2010/11/101108140408.htm>.
American Association for Cancer Research. (2010, November 8). Gefitinib may have chemopreventive benefits in pancreatic cancer. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2010/11/101108140408.htm
American Association for Cancer Research. "Gefitinib may have chemopreventive benefits in pancreatic cancer." ScienceDaily. www.sciencedaily.com/releases/2010/11/101108140408.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
US to Track Everyone Coming from Ebola Nations

US to Track Everyone Coming from Ebola Nations

AP (Oct. 22, 2014) Stepping up their vigilance against Ebola, federal authorities said Wednesday that everyone traveling into the US from Ebola-stricken nations will be monitored for symptoms for 21 days. (Oct. 22) Video provided by AP
Powered by NewsLook.com
Doctors Help Paralysed Man Walk Again, Patient in Disbelief

Doctors Help Paralysed Man Walk Again, Patient in Disbelief

AFP (Oct. 22, 2014) Polish doctors describe how they helped a paralysed man walk again, with the patient in disbelief at the return of sensation to his legs. Duration: 1:04 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins